Posted on: February 4, 2022
Kelly T. McKee, Jr., MD ’76, MPH. has been appointed to serve as the chief medical officer (CMO) for GeoVax Labs, Inc., a biotechnology company specializing in developing human vaccines and cancer immunotherapies.
McKee brings over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, MD, United States, where he held a variety of leadership positions in virology, immunology, preventive medicine, and clinical research and development with the U.S. Army, retiring as a Colonel in 2001. McKee subsequently served as state epidemiologist in North Carolina, and as senior director of clinical research at DynPort Vaccine Company. He then held multiple leadership roles, including vice president and managing director of public health and government services, and vice president for vaccines and public health in the Infectious Diseases and Vaccines Center of Excellence, at Quintiles/QuintilesIMS (now IQVIA) for more than 10 years. He now provides contract clinical development services to biopharmaceutical industry in infectious diseases and related areas.
McKee earned an MD from the University of Virginia School of Medicine, and a Master of Public Health degree from Johns Hopkins University School of Hygiene and Public Health in Baltimore, MD. Over the course of a successful military and private-sector career, he has also earned multiple board and advisory appointments, certifications, grants, civilian honors, and inductions and fellowships to some of the world’s most prestigious medical associations. He has authored or co-authored more than 100 peer-reviewed publications and book chapters.